Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus johnsonii extracellular vesicles
- Development stage
- Preclinical
- Lead developer
- University of Florida
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus johnsonii extracellular vesicles (EVs) are nano-sized, membrane-bound vesicles derived from the probiotic bacterium Lactobacillus johnsonii, particularly the N6.2 strain. These EVs encapsulate bacterial proteins, nucleic acids, and metabolites, including key active proteins like GroL (a chaperonin), GAPDH, and the Sdp-SH3b2 domain. They function as immunomodulators by promoting M2 macrophage polarization, regulating the Th17/Treg balance, and enhancing gut barrier homeostasis. Recent research highlights their ability to mitigate epithelial cuprotosis in ulcerative colitis by interacting with the host copper importer SLC31A1 to reduce intracellular copper accumulation. They are currently being investigated in academic settings for potential therapeutic applications in inflammatory bowel disease, osteoarthritis, and viral infections.
- Other names
- L. johnsonii-derived EVsL. johnsonii EVsGroL-enriched extracellular vesicles
02
Targets
2'-5'-oligoadenylate synthetase / ribonuclease L pathwaySTAT3 (Signal Transducer and Activator of Transcription 3)
Beyond the preview
Go deeper on Lactobacillus johnsonii extracellular vesicles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus johnsonii extracellular vesicles.